
Chinese General Practice ›› 2023, Vol. 26 ›› Issue (07): 886-892.DOI: 10.12114/j.issn.1007-9572.2022.0493
Special Issue: 消化系统疾病最新文章合辑
• Review • Previous Articles Next Articles
Received:2022-07-01
Revised:2022-12-11
Published:2023-03-05
Online:2023-01-05
Contact:
YANG Jinhui
通讯作者:
杨晋辉
作者简介:基金资助:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2022.0493
| 项目 | 东方(APASL发布的诊断标准/CMA发布的诊断标准) | 西方(NACSELD发布的诊断标准/EASL发布的诊断标准) | |
|---|---|---|---|
| 制定ACLF诊断标准的目的 | 明确最佳救治时机 | 筛选肝移植人群 | |
| 标准制定研究纳入的慢性肝病患者的主要病因 | HBV感染 | 酒精性肝病,其次是HCV感染 | |
| 对慢性肝病基础的界定 | APASL发布的诊断标准:肝硬化或非肝硬化慢性肝病(排除既往发生过肝硬化失代偿的患者) CMA发布的诊断标准:肝硬化或非肝硬化 | 肝硬化 | |
| 对急性诱发因素的界定 | HBV再激活 | 细菌感染、酗酒 | |
| 对急性肝损伤时间窗的界定 | 4周 | 未明确 | |
| 对器官/系统功能衰竭的界定 | |||
| 强调重点 | 肝脏本身功能衰竭 | 全身多器官/系统功能衰竭 | |
| 对血清TBil水平的界定 | APASL发布的诊断标准:血清TBil≥5 mg/dl CMA发布的诊断标准:血清TBil≥10倍基线值,或每天上升≥17.1 μmol/L | NACSELD发布的诊断标准:未纳入 EASL发布的诊断标准:血清TBil≥12 mg/dl | |
| 对凝血功能障碍的界定 | INR≥1.5或PTA<40% | NACSELD发布的诊断标准:未纳入 EASL发布的诊断标准:INR≥2.5,或血小板计数≤20×103/μl | |
| 对肾衰竭的界定 | 未纳入 | NACSELD发布的诊断标准:需要接受肾脏替代治疗 EASL发布的诊断标准:血肌酐≥2 mg/dl(肾衰竭)、1.5~1.9 mg/dl(肾功能损害) | |
| 对呼吸系统衰竭的界定 | 未纳入 | NACSELD发布的诊断标准:需要机械通气设备支持 EASL发布的诊断标准:PaO2/FiO2≤200,89<SpO2/FiO2≤214或需要机械通气设备支持 | |
| 对循环系统衰竭的界定 | 未纳入 | NACSELD发布的诊断标准:补液后MAP<60 mm Hg或收缩压较基线值下降40 mm Hg EASL发布的诊断标准:使用多巴胺、特利加压素等血管活性药物维持血压 | |
| 对脑衰竭的界定 | 任意等级的肝性脑病均有诊断意义 | NACSELD发布的诊断标准:Ⅲ/Ⅳ级肝性脑病 EASL发布的诊断标准:Ⅲ/Ⅳ级肝性脑病;合并其他器官/系统功能衰竭时,Ⅰ/Ⅱ级肝性脑病有诊断意义 | |
| 腹腔积液 | 有诊断意义 | 未纳入 | |
| ACLF严重程度评估 | APASL发布的诊断标准:AARC评分系统 CMA发布的诊断标准:将ACLF分为前期、早期、中期、晚期 | NACSELD发布的诊断标准:未明确 EASL发布的诊断标准:CLIF-SOFA评分系统 | |
Table 1 Differences between eastern and western diagnostic criteria of ACLF
| 项目 | 东方(APASL发布的诊断标准/CMA发布的诊断标准) | 西方(NACSELD发布的诊断标准/EASL发布的诊断标准) | |
|---|---|---|---|
| 制定ACLF诊断标准的目的 | 明确最佳救治时机 | 筛选肝移植人群 | |
| 标准制定研究纳入的慢性肝病患者的主要病因 | HBV感染 | 酒精性肝病,其次是HCV感染 | |
| 对慢性肝病基础的界定 | APASL发布的诊断标准:肝硬化或非肝硬化慢性肝病(排除既往发生过肝硬化失代偿的患者) CMA发布的诊断标准:肝硬化或非肝硬化 | 肝硬化 | |
| 对急性诱发因素的界定 | HBV再激活 | 细菌感染、酗酒 | |
| 对急性肝损伤时间窗的界定 | 4周 | 未明确 | |
| 对器官/系统功能衰竭的界定 | |||
| 强调重点 | 肝脏本身功能衰竭 | 全身多器官/系统功能衰竭 | |
| 对血清TBil水平的界定 | APASL发布的诊断标准:血清TBil≥5 mg/dl CMA发布的诊断标准:血清TBil≥10倍基线值,或每天上升≥17.1 μmol/L | NACSELD发布的诊断标准:未纳入 EASL发布的诊断标准:血清TBil≥12 mg/dl | |
| 对凝血功能障碍的界定 | INR≥1.5或PTA<40% | NACSELD发布的诊断标准:未纳入 EASL发布的诊断标准:INR≥2.5,或血小板计数≤20×103/μl | |
| 对肾衰竭的界定 | 未纳入 | NACSELD发布的诊断标准:需要接受肾脏替代治疗 EASL发布的诊断标准:血肌酐≥2 mg/dl(肾衰竭)、1.5~1.9 mg/dl(肾功能损害) | |
| 对呼吸系统衰竭的界定 | 未纳入 | NACSELD发布的诊断标准:需要机械通气设备支持 EASL发布的诊断标准:PaO2/FiO2≤200,89<SpO2/FiO2≤214或需要机械通气设备支持 | |
| 对循环系统衰竭的界定 | 未纳入 | NACSELD发布的诊断标准:补液后MAP<60 mm Hg或收缩压较基线值下降40 mm Hg EASL发布的诊断标准:使用多巴胺、特利加压素等血管活性药物维持血压 | |
| 对脑衰竭的界定 | 任意等级的肝性脑病均有诊断意义 | NACSELD发布的诊断标准:Ⅲ/Ⅳ级肝性脑病 EASL发布的诊断标准:Ⅲ/Ⅳ级肝性脑病;合并其他器官/系统功能衰竭时,Ⅰ/Ⅱ级肝性脑病有诊断意义 | |
| 腹腔积液 | 有诊断意义 | 未纳入 | |
| ACLF严重程度评估 | APASL发布的诊断标准:AARC评分系统 CMA发布的诊断标准:将ACLF分为前期、早期、中期、晚期 | NACSELD发布的诊断标准:未明确 EASL发布的诊断标准:CLIF-SOFA评分系统 | |
| 第一作者 | APASL发布的ACLF诊断标准 | EASL发布的ACLF诊断标准 | NACSELD发布的ACLF诊断标准 | COSSH发布的ACLF诊断标准 | CMA发布的ACLF诊断标准 | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| 28 d死亡率 | 90 d死亡率 | 28 d死亡率 | 90 d死亡率 | 28 d死亡率 | 90 d死亡率 | 28 d死亡率 | 90 d死亡率 | 28 d死亡率 | 90 d死亡率 | |
| SELVA RAJOO等[ | — | 35.7 | — | 53.3 | — | — | — | — | — | — |
| CAO等[ | — | — | 41.6 | 62.9 | 62.9 | 94.3 | — | — | — | — |
| WU等[ | 0.7 | 5.1 | 40.7 | 63.2 | — | — | — | — | — | — |
| DHIMAN等[ | 36.8 | 68.4 | 47.4 | 71.1 | — | — | — | — | — | — |
| LEÃO等[ | 50.0 | 64.3 | 53.5 | 78.0 | 83.3 | 100.0 | — | — | — | — |
| SHI等[ | — | — | 49.4 | 63.0 | — | — | — | — | — | — |
| ZHANG等[ | — | 13.1 | — | — | — | — | — | — | 25.3 | — |
| DONG等[ | — | — | 50.2 | 57.2% | — | — | 37.1 | 47.5 | — | — |
| XU等[ | 24.8 | 42.9 | — | — | — | — | — | — | — | — |
Table 2 The performance of five diagnostic criteria for ACLF in the prediction of prognosis in ACLF patients
| 第一作者 | APASL发布的ACLF诊断标准 | EASL发布的ACLF诊断标准 | NACSELD发布的ACLF诊断标准 | COSSH发布的ACLF诊断标准 | CMA发布的ACLF诊断标准 | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| 28 d死亡率 | 90 d死亡率 | 28 d死亡率 | 90 d死亡率 | 28 d死亡率 | 90 d死亡率 | 28 d死亡率 | 90 d死亡率 | 28 d死亡率 | 90 d死亡率 | |
| SELVA RAJOO等[ | — | 35.7 | — | 53.3 | — | — | — | — | — | — |
| CAO等[ | — | — | 41.6 | 62.9 | 62.9 | 94.3 | — | — | — | — |
| WU等[ | 0.7 | 5.1 | 40.7 | 63.2 | — | — | — | — | — | — |
| DHIMAN等[ | 36.8 | 68.4 | 47.4 | 71.1 | — | — | — | — | — | — |
| LEÃO等[ | 50.0 | 64.3 | 53.5 | 78.0 | 83.3 | 100.0 | — | — | — | — |
| SHI等[ | — | — | 49.4 | 63.0 | — | — | — | — | — | — |
| ZHANG等[ | — | 13.1 | — | — | — | — | — | — | 25.3 | — |
| DONG等[ | — | — | 50.2 | 57.2% | — | — | 37.1 | 47.5 | — | — |
| XU等[ | 24.8 | 42.9 | — | — | — | — | — | — | — | — |
| [1] |
|
| [2] |
|
| [3] |
|
| [4] |
|
| [5] |
|
| [6] |
|
| [7] |
|
| [8] |
|
| [9] |
|
| [10] |
|
| [11] |
|
| [12] |
|
| [13] |
|
| [14] |
|
| [15] |
|
| [16] |
|
| [17] |
|
| [18] |
|
| [19] |
|
| [20] |
|
| [21] |
|
| [22] |
中华医学会感染病学分会肝衰竭与人工肝学组,中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊疗指南[J]. 中华肝脏病杂志,2006,14(9):643-646.
|
| [23] |
中华医学会感染病学分会肝衰竭与人工肝学组,中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2012年版)[J]. 中华肝脏病杂志,2013,21(3):177-183.
|
| [24] |
中华医学会感染病学分会肝衰竭与人工肝学组,中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2018年版)[J]. 中华肝脏病杂志,2019,27(1):18-26.
|
| [25] |
|
| [26] |
李晨,朱冰,吕飒,等. 乙型肝炎病毒相关慢加急性肝衰竭前期患者诊断标准的探讨[J]. 中华肝脏病杂志,2018,26(2):130-135.
|
| [27] |
李海. CATCH-LIFE中国多中心研究对慢加急性肝衰竭前期概念验证和新思路[J]. 中华肝脏病杂志,2020,28(4):307-309.
|
| [28] |
|
| [29] |
穆秀颖,童晶晶,许祥,等. 世界胃肠病组织慢加急性肝衰竭分型的临床应用[J]. 国际流行病学传染病学杂志,2018,45(6):390-394. DOI:10.3760/cma.j.issn.1673-4149.2018.06.004.
|
| [30] |
徐曼曼,孔明,曹影影,等. 慢加急性肝衰竭分型新视点:基于临床转归的动态分型新标准[J].中华肝脏病杂志,2020,28(4):319-325.
|
| [31] |
|
| [32] |
|
| [33] |
|
| [34] |
|
| [35] |
|
| [36] |
|
| [37] |
|
| [38] |
|
| [39] |
|
| [40] |
|
| [1] | FENG Yuxi, WANG Jinjin, CAI Yi, ZHU Runzhi, ZHU Qin. Research Progress on Protein Lactylation in Kidney Diseases [J]. Chinese General Practice, 2026, 29(21): 3056-3063. |
| [2] | PAN Ziyun, YIN Hao, LIN Zhirou, MAO Jingyi, HUANG Yan, LUO Yanhua, XIAO Jiafu, HU Yin. From Mechanism to Therapy: Diabetic Autonomic Neuropathy [J]. Chinese General Practice, 2026, 29(21): 2982-2988. |
| [3] | LI Wenping, CHEN Jianhua, XU Jiapei, JIN Xue, PAN Zihan, CHI Chunhua. A Scoping Review on the Empowerment of Community Elderly Health Services by Digital-Intelligent Health Management Platforms [J]. Chinese General Practice, 2026, 29(21): 2938-2949. |
| [4] | CHENG Yu, HAN Shiyao, SUN Ping, XIANG Juan, YANG Hui, LI Dongze, ZHENG Li, LIAO Xiaoyang. Analysis of Socioeconomic and Demographic Challenges in Chronic Disease Management [J]. Chinese General Practice, 2026, 29(20): 2800-2807. |
| [5] | YAN Wen, ZHANG Hanzhi, JIN Hua, QIAN Jie, YU Dehua. Study on the Diagnosis and Treatment Capacity for Depressive Disorders in Community Health Service Institutions in Shanghai [J]. Chinese General Practice, 2026, 29(20): 2790-2799. |
| [6] | CHEN Yiping, ZHANG Jianmei, LI Yanhu, LI Rui, ZHANG Ruiping, YANG Ping. Advances in the Diagnosis and Treatment of Post-COVID-19 Condition of Myocardial Injury [J]. Chinese General Practice, 2026, 29(18): 2585-2592. |
| [7] | AN Xian, HUANG Peng, REN Jingjing. Investigation on the Cognition and Current Status of General Practitioners in the Multidisciplinary Diagnosis and Treatment of Medically Unexplained Symptoms [J]. Chinese General Practice, 2026, 29(18): 2472-2481. |
| [8] | ZHANG Mingyue, HOU Yan. Research Progress of Exhaled Nitric Oxide and Alveolar Nitric Oxide in Interstitial Lung Diseases [J]. Chinese General Practice, 2026, 29(18): 2571-2576. |
| [9] | FAN Meixiang, YAN Yunyun, HUANG Yanyan. Interpretation and Discussion of Guidelines for Preventive Activities in General Practice: Bladder Cancer [J]. Chinese General Practice, 2026, 29(18): 2450-2453. |
| [10] | General Practice Branch of Cross-straits Medicine Exchange Association, General Practice Branch of Zhejiang Medical Association, General Undifferentiated Disease Professional Committee of Zhejiang Society of Mathematical Medicine, Chinese Geriatrics Society. Expert Consensus on the Diagnosis, Treatment, and Management of Numbness (2025) [J]. Chinese General Practice, 2026, 29(18): 2433-2449. |
| [11] | MA Xiaoyu, MA Xiaomei, WU Guozhi, ZHENG Ya, GUO Qinghong. Research Progress of Neutrophil Extracellular Traps in Gastric Cancer [J]. Chinese General Practice, 2026, 29(17): 2425-2432. |
| [12] | LUAN Xiaoqing, SUN Jingjing, LI Xiaoling, WANG Manxia. Research Progress on Potential Biomarkers of Neuromyelitis Optica Spectrum Disorder [J]. Chinese General Practice, 2026, 29(17): 2418-2424. |
| [13] | LI Jiawei, GE Aoqi, GAO Xinyi, LI Juanjuan, YUAN Beibei. The Concept, Connotation, and Pathways of the Integration of Medical Care and Preventive Services in China: a Systematic Review [J]. Chinese General Practice, 2026, 29(16): 2156-2166. |
| [14] | WANG Yang, JIN Hua, YANG Sen, YANG Hui, YU Dehua. Reconfiguring the Functional Features of Primary Care in a Non-gatekeeping Context: a 15-Year Mixed-methods Systematic Review from China [J]. Chinese General Practice, 2026, 29(16): 2140-2155. |
| [15] | YAO Dingye, LUO Guiping, SUN Junsheng, LI Hui. Research Progress on Identifying Bipolar Ⅱ Disorder and Depressive Disorder in Primary Care [J]. Chinese General Practice, 2026, 29(15): 2092-2099. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||